Who are Pepcid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Axid Ar, Tagamet, Famotidine 20 MG.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/famotidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Pepcid — Competitive Intelligence Brief

Pepcid (famotidine) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histamine-2 Receptor Antagonist [EPC]. Area: Cardiovascular.

marketed Histamine-2 Receptor Antagonist [EPC] Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Pepcid (famotidine) — Generic (originally Yamanouchi/Merck). Competitively blocks histamine H2 receptors on gastric parietal cells, reducing basal and stimulated acid secretion.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pepcid TARGET	famotidine	Generic (originally Yamanouchi/Merck)	marketed	Histamine-2 Receptor Antagonist [EPC]	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2	1986-10-01
Axid Ar	NIZATIDINE		marketed	Histamine-2 Receptor Antagonist [EPC]	Histamine H2 receptor	1988-01-01
Tagamet	CIMETIDINE		marketed	Histamine-2 Receptor Antagonist [EPC]	Histamine H2 receptor	1977-01-01
Famotidine 20 MG	Famotidine 20 MG	Chattogram General Hospital	marketed	Histamine-2 Receptor Antagonist [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histamine-2 Receptor Antagonist [EPC] class)

· 2 drugs in this class
Chattogram General Hospital · 1 drug in this class
Generic (originally Yamanouchi/Merck) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pepcid — Competitive Intelligence Brief. https://druglandscape.com/ci/famotidine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab